Drug Approval | December 16, 2021
U.S. FDA approves Bristol Myers Squibb’s Orencia
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
Natco Pharma has reported consolidated financial results for the period ended September 30, 2021
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
Gini Health works in the domain of personalised healthcare
Filing marks first protein-based vaccine submitted to MHRA for authorization
Key takeaways of recent quarter & conference call highlights
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
Subscribe To Our Newsletter & Stay Updated
